FDA clears ovarian cancer drug for hard-to-treat tumors – SFGate
CNBC |
FDA clears ovarian cancer drug for hard-to-treat tumors
SFGate WASHINGTON — Federal health officials have approved a new option for some women battling ovarian cancer: a drug that attacks a genetic mutation seen in a subset of hard-to-treat tumors. The Food and Drug Administration cleared the drug, Rubraca, from … FDA Grants Niraparib Priority Review in Ovarian Cancer Tesaro bags priority review, June PDUFA for PARP inhibitor Tesaro Ovarian Cancer Drug Gets Priority Review After FDA OKs Clovis Med |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.